Overlapping molecular signatures in Parkinson's patient leukocytes before and after treatment and in mouse model brain regions

CNS and Neurological Disorders - Drug Targets

Volumn 12, Issue 8, 2013, Pages 1086-1093

  Soreq, Lilach ^a   Bergman, Hagai ^a   Israel, Zvi ^b   Soreq, Hermona ^a,c  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c Institute of Life Sciences   (Israel)

Author keywords

Alternative splicing; Blood leukocytes; Deep brain stimulation; Early diagnosis; Microarrays; microRNAs; Molecular signature; Mouse models; Parkinson's disease; RNA Seq

Indexed keywords

INTERFERON REGULATORY FACTOR 4; INTERLEUKIN 1; INTERLEUKIN 8; MESSENGER RNA; MICRORNA; TUMOR NECROSIS FACTOR ALPHA;

ALTERNATIVE RNA SPLICING; BRAIN DEPTH STIMULATION; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; INCIDENCE; INFLAMMATION; MICROARRAY ANALYSIS; NONHUMAN; PARKINSON DISEASE; PREVALENCE; PROTEIN DOMAIN; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; ANIMAL; BRAIN; COMPARATIVE STUDY; DISEASE MODEL; GENE THERAPY; GENETICS; IMMUNOLOGY; LEUKOCYTE; METABOLISM; MOUSE; PATHOLOGY; TREATMENT OUTCOME; TRENDS;

ANIMALS; BRAIN; DEEP BRAIN STIMULATION; DISEASE MODELS, ANIMAL; GENETIC THERAPY; HUMANS; LEUKOCYTES; MICE; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 84891724352     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Greffard, S.; Verny, M.; Bonnet, A.M.; Seilhean, D.; Hauw, J.J.; Duyckaerts, C. A stable proportion of Lewy body bearing neurons in the substantia nigra suggests a model in which the Lewy body causes neuronal death. Neurobiol. Aging, 2010, 31, 99-103.
2. Iseki, E.; Marui, W.; Kosaka, K.; Akiyama, H.; Ueda, K.; Iwatsubo, T. Degenerative terminals of the perforant pathway are human alpha-synucleinimmunoreactive in the hippocampus of patients with diffuse Lewy body disease. Neurosci. Lett., 1998, 258, 81-84.
3. Orimo, S.; Uchihara, T.; Nakamura, A.; Mori, F.; Kakita, A.; Wakabayashi, K.; Takahashi, H. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. Brain, 2008, 131, 642-650.
4. Luk, K.C.; Kehm, V.; Carroll, J.; Zhang, B.; O'Brien, P.; Trojanowski, J.Q.; Lee, V.M. Pathological alpha-synuclein transmission initiates Parkinsonlike neurodegeneration in nontransgenic mice. Science, 2012, 338, 949-953.
5. Sanchez-Danes, A.; Consiglio, A.; Richaud, Y.; Rodriguez-Piza, I.; Dehay, B.; Edel, M.; Bove, J.; Memo, M.; Vila, M.; Raya, A.; Izpisua Belmonte, J.C. Efficient generation of A9 midbrain dopaminergic neurons by lentiviral delivery of LMX1A in human embryonic stem cells and induced pluripotent stem cells. Hum. Gene Ther., 2012, 23, 56-69.
6. Sanchez-Danes, A.; Richaud-Patin, Y.; Carballo-Carbajal, I.; Jimenez-Delgado, S.; Caig, C.; Mora, S.; Di, G.C.; Ezquerra, M.; Patel, B.; Giralt, A.; Canals, J.M.; Memo, M.; Alberch, J.; Lopez-Barneo, J.; Vila, M.; Cuervo, A.M.; Tolosa, E.; Consiglio, A.; Raya, A. Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease. EMBO Mol. Med., 2012, 4, 380-395.
7. Cooper, O.; Seo, H.; Andrabi, S.; Guardia-Laguarta, C.; Graziotto, J.; Sundberg, M.; McLean, J.R.; Carrillo-Reid, L.; Xie, Z.; Osborn, T.; Hargus, G.; Deleidi, M.; Lawson, T.; Bogetofte, H.; Perez-Torres, E.; Clark, L.; Moskowitz, C.; Mazzulli, J.; Chen, L.; Volpicelli-Daley, L.; Romero, N.; Jiang, H.; Uitti, R.J.; Huang, Z.; Opala, G.; Scarffe, L.A.; Dawson, V.L.; Klein, C.; Feng, J.; Ross, O.A.; Trojanowski, J.Q.; Lee, V.M.; Marder, K.; Surmeier, D.J.; Wszolek, Z.K.; Przedborski, S.; Krainc, D.; Dawson, T.M.; Isacson, O. Pharmacological Rescue of Mitochondrial Deficits in iPSCDerived Neural Cells from Patients with Familial Parkinson's Disease. Sci. Transl. Med., 2012, 4, 141-90.
8. Fiorentini, C.; Rizzetti, M.C.; Busi, C.; Bontempi, S.; Collo, G.; Spano, P.; Missale, C. Loss of synaptic D1 dopamine/N-methyl-D-aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat. Mol. Pharmacol., 2006, 69, 805-812.
9. Maggio, R.; Aloisi, G.; Silvano, E.; Rossi, M.; Millan, M.J. Heterodimerization of dopamine receptors: new insights into functional and therapeutic significance. Parkinson. Relat. Disord., 2009, 15 (Suppl 4), S2-S7.
10. Fiorentini, C.; Busi, C.; Gorruso, E.; Gotti, C.; Spano, P.; Missale, C. Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization. Mol. Pharmacol., 2008, 74, 59-69.
11. Ferre, S.; Quiroz, C.; Woods, A.S.; Cunha, R.; Popoli, P.; Ciruela, F.; Lluis, C.; Franco, R.; Azdad, K.; Schiffmann, S.N. An update on adenosine A2A-dopamine D2 receptor interactions: implications for the function of G protein-coupled receptors. Curr. Pharm. Des., 2008, 14, 1468-1474.
12. Fiorentini, C.; Busi, C.; Spano, P.; Missale, C. Role of receptor heterodimers in the development of L-dopa-induced dyskinesias in the 6-hydroxydopamine rat model of Parkinson's disease. Parkinson. Relat. Disord., 2008, 14 (Suppl 2), S159-S164.
13. Fiorentini, C.; Gardoni, F.; Spano, P.; Di, L.M.; Missale, C. Regulation of dopamine D1 receptor trafficking and desensitization by oligomerization with glutamate N-methyl-D-aspartate receptors. J. Biol. Chem., 2003, 278, 20196-20202. 133 and pitx3 genes in parkinson's disease. Am. J. Med. Genet. Part B Neuropsychiatric Genet., 2010, 153B (6), 1234-1239.
14. Doxakis, E. Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153. J. Biol. Chem., 2010, 285 (17), 12726-12734.
15. Junn, E.; Lee, K.W.; Jeong, B.S.; Chan, T.W.; Im, J.Y.; Mouradian, M.M. Repression of α-synuclein expression and toxicity by microrna-7. Proc. Natl. Acad. Sci. USA, 2009, 106 (31), 13052-13057.
16. Martins, M.; Rosa, A.; Guedes, L.C.; Fonseca, B.V.; Gotovac, K.; Violante, S.; Mestre, T.; Coelho, M.; Rosa, M.M.; Martin, E.R. Convergence of mirna expression profiling, α-synuclein interacton and gwas in parkinson's disease. PloS One, 2011, 6 (10), e25443.
17. Greggio, E.; Bisaglia, M.; Civiero, L.; Bubacco, L. Leucine-rich repeat kinase 2 and alpha-synuclein: intersecting pathways in the pathogenesis of Parkinson's disease? Mol Neurodegener., 2011, 6 (1), 6.
18. Smith, W.W.; Pei, Z.; Jiang, H.; Moore, D.J.; Liang, Y.; West, A.B.; Dawson, V.L.; Dawson, T.M.; Ross, C.A. Leucine-rich repeat kinase 2 (lrrk2) interacts with parkin, and mutant lrrk2 induces neuronal degeneration. Proc. Natl. Acad. Sci. USA, 2005, 102 (51), 18676-18681.
19. Lin, X.; Parisiadou, L.; Gu, X.L.; Wang, L.; Shim, H.; Sun, L.; Xie, C.; Long, C.X.; Yang, W.J.; Ding, J. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by parkinson'sdisease-related mutant [alpha]-synuclein. Neuron, 2009, 64 (6), 807-827.
20. Ruby, J.G.; Jan, C.H.; Bartel, D.P. Intronic microrna precursors that bypass drosha processing. Nature, 2007, 448 (7149), 83-86.
21. Lares, M.R.; Rossi, J.J.; Ouellet, D.L. Rnai and small interfering rnas in human disease therapeutic applications. Trends Biotechnol., 2010, 28 (11), 570-579.
22. Sibley, C.R.; Seow, Y.; Curtis, H.; Weinberg, M.S.; Wood, M.J.A. Silencing of parkinson's disease-associated genes with artificial mirtron mimics of mir-1224. Nucleic Acids Res., 2012, 40 (19), 9863-9875.
23. Bergman, H.; Wichmann, T.; DeLong, M.R. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science, 1990, 249 (4975), 1436.
24. Shehadeh, L.A.; Yu, K.; Wang, L.; Guevara, A.; Singer, C.; Vance, J.; Papapetropoulos, S. Srrm2, a potential blood biomarker revealing high alternative splicing in parkinson's disease. PloS One, 2010, 5 (2), e9104.
25. Potashkin, J.A.; Santiago, J.A.; Ravina, B.M.; Watts, A.; Leontovich, A.A. Biosignatures for parkinson's disease and atypical parkinsonian disorders patients. PloS One, 2012, 7 (8), e43595.
26. Molochnikov, L.; Rabey, J.M.; Dobronevsky, E.; Bonucelli, U.; Ceravolo, R.; Frosini, D.; Grunblatt, E.; Riederer, P.; Jacob, C.; Aharon-Peretz, J.; Bashenko, Y.; Youdim, M.B.; Mandel, S.A. A molecular signature in blood identifies early parkinson's disease. Mol. Neurodegener., 2012, 7, 26.
27. Nagai, Y.; Ueno, S.; Saeki, Y.; Soga, F.; Hirano, M.; Yanagihara, T. Decrease of the d3 dopamine receptor mrna expression in lymphocytes from patients with parkinson's disease. Neurology, 1996, 46 (3), 791-795.
28. Ben-Shaul, Y.; Bergman, H.; Soreq, H. Identifying subtle interrelated changes in functional gene categories using continuous measures of gene expression. Bioinformatics, 2005, 21 (7), 1129-1137.
29. Benmoyal-Segal, L.; Soreq, L.; Ben-Shaul, Y.; Ben-Ari, S.; Ben-Moshe, T.; Aviel, S.; Bergman, H.; Soreq, H. Adaptive alternative splicing correlates with less environmental risk of parkinsonism. Neurodegener. Dis., 2012, 9 (2), 87-98.
30. Langston, J.W.; Ballard, P.; Tetrud, J.W.; Irwin, I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science, 1983, 219 (4587), 979-980.
31. Fleming, S.M.; Fernagut, P.O.; Chesselet, M.F. Genetic mouse models of parkinsonism: Strengths and limitations. NeuroRx, 2005, 2 (3), 495-503.
32. Harris, M.; Clark, J.; Ireland, A.; Lomax, J.; Ashburner, M.; Foulger, R.; Eilbeck, K.; Lewis, S.; Marshall, B.; Mungall, C. The gene ontology (go) database and informatics resource. Nucleic Acids Res., 2004, 32 (Database issue), D258.
33. Soreq, L.; Ben-Shaul, Y.; Israel, Z.; Bergman, H.; Soreq, H. Metaanalysis of genetic and environmental parkinson's disease models reveals a common role of mitochondrial protection pathways. Neurobiol. Dis., 2012, 45 (3), 1018-1030.
34. Cooper, O.; Seo, H.; Andrabi, S.; Guardia-Laguarta, C.; Graziotto, J.; Sundberg, M.; McLean, J.R.; Carrillo-Reid, L.; Xie, Z.; Osborn, T. Pharmacological rescue of mitochondrial deficits in ipsc-derived neural cells from patients with familial parkinson's disease. Sci. Transl. Med., 2012, 4 (141), 141ra90-ra90.
35. Moore, D.J.; West, A.B.; Dawson, V.L.; Dawson, T.M. Molecular pathophysiology of parkinson's disease. Annu. Rev. Neurosci., 2005, 28, 57-87.
36. Soreq, L.; Gilboa-Geffen, A.; Berrih-Aknin, S.; Lacoste, P.; Darvasi, A.; Soreq, E.; Bergman, H.; Soreq, H. Identifying alternative hypersplicing signatures in mg-thymoma by exon arrays. PloS One, 2008, 3 (6), e2392.
37. Grünblatt, E. Parkinson's disease: Molecular risk factors. Parkinson. Relat. Disord., 2012, 18, S45-S48.
38. Twine, N.A.; Janitz, K.; Wilkins, M.R.; Janitz, M. Whole transcriptome sequencing reveals gene expression and splicing differences in brain regions affected by alzheimer's disease. PloS One, 2011, 6 (1), e16266.
39. Guerau-de-Arellano, M.; Alder, H.; Ozer, H.G.; Lovett-Racke, A.; Racke, M.K. Mirna profiling for biomarker discovery in multiple sclerosis: From microarray to deep sequencing. J. Neuroimmunol., 2012, 248 (1-2), 32-39.
40. Jiao, S.; Gurevich, V.; Wolff, J.A. Long-term correction of rat model of parkinson's disease by gene therapy. Nature, 1993, 362 (6419), 450-453.
41. Kaplitt, M.G.; Feigin, A.; Tang, C.; Fitzsimons, H.L.; Mattis, P.; Lawlor, P.A.; Bland, R.J.; Young, D.; Strybing, K.; Eidelberg, D.; During, M.J. Safety and tolerability of gene therapy with an adenoassociated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet, 2007, 369 (9579), 2097-2105.
42. Mittermeyer, G.; Christine, C.W.; Rosenbluth, K.H.; Baker, S.L.; Starr, P.; Larson, P.; Kaplan, P.L.; Forsayeth, J.; Aminoff, M.J.; Bankiewicz, K.S. Long-term evaluation of a phase 1 study of aadc gene therapy for parkinson's disease. Hum. Gene Ther., 2012, 23 (4), 377-381.
43. Bjorklund, A.; Kirik, D.; Rosenblad, C.; Georgievska, B.; Lundberg, C.; Mandel, R. Towards a neuroprotective gene therapy for parkinson's disease: Use of adenovirus, aav and lentivirus vectors for gene transfer of gdnf to the nigrostriatal system in the rat parkinson model. Brain Res., 2000, 886 (1), 82-98.
44. Luo, J.; Kaplitt, M.G.; Fitzsimons, H.L.; Zuzga, D.S.; Liu, Y.; Oshinsky, M.L.; During, M.J. Subthalamic gad gene therapy in a parkinson's disease rat model. Sci. Signal., 2002, 298 (5592), 425.
45. Zheng, B.; Liao, Z.; Locascio, J.J.; Lesniak, K.A.; Roderick, S.S.; Watt, M.L.; Eklund, A.C.; Zhang-James, Y.; Kim, P.D.; Hauser, M.A. Pgc-1α, a potential therapeutic target for early intervention in parkinson's disease. Sci. Transl. Med., 2010, 2 (52), 52-73.
46. Maarouf, C.L.; Beach, T.G.; Adler, C.H.; Shill, H.A.; Sabbagh, M.N.; Wu, T.; Walker, D.G.; Kokjohn, T.A.; Roher, A.E.; Arizona, P. Cerebrospinal fluid biomarkers of neuropathologically diagnosed parkinson's disease subjects. Neurol. Res., 2012, 34 (7), 669.
47. Esteller, M. Non-coding rnas in human disease. Nat. Rev. Genet., 2011, 12 (12), 861-874.